Pediatric Oncology Branch: Our Clinical Trials
-
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0023Investigator Udo Rudloff, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number -
Development and Psychometric Testing of a Pediatric Chronic Graft- Versus-Host Disease (GVHD) Symptom Scale (PCSS)
Open - RecruitingNCI Protocol ID NCI-19-C-0131Investigator Lori Wiener, Ph.D., DCSW, LCSW-C -
Development and Psychometric Testing of a Pediatric Chronic GVHD Symptom Scale (PCSS)
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-19-C-0121Investigator Lori Wiener, Ph.D., DCSW, LCSW-C -
Natural History Study of Children and Adults with Chordoma
Open - RecruitingNCI Protocol ID NCI-19-C-0082Investigator Brigitte C. Widemann, M.D. -
A Phase 2 Trial of The MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Open - RecruitingNCI Protocol ID NCI-19-C-0061Investigator Brigitte C. Widemann, M.D. -
Natural History and Biospecimen Accrual Study for Children and Adults with Rare Solid Tumors
Open - RecruitingNCI Protocol ID NCI-19-C-0016Investigator Jaydira Del Rivero, M.D. -
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Open - RecruitingNCI Protocol ID NCI-18-C-0126Investigator John W. Glod, M.D. -
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
Open - RecruitingNCI Protocol ID NCI-18-C-0119Investigator Brigitte C. Widemann, M.D. -
Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults with Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF)
Open - RecruitingNCI Protocol ID NCI-18-C-0102Investigator Andrea M. Gross, M.D.Share this trial: Referral ContactsContact Name Phone Number Jennifer DeSanto 240-858-3403 Jennifer Desanto 240.858.3403 -
Pilot Study of Medication Adherence in Children, Adolescents, and Adults with Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
Open - RecruitingNCI Protocol ID NCI-18-C-0093Investigator Staci Martin Peron, Ph.D. -
Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High Risk Cancer and Their Caregivers
Open - RecruitingNCI Protocol ID NCI-18-C-0080Investigator Staci Martin Peron, Ph.D. -
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors#xD;
Open - RecruitingNCI Protocol ID NCI-18-C-0062Investigator Brigitte C. Widemann, M.D. -
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Open - RecruitingNCI Protocol ID NCI-18-C-0059Investigator Nirali N. Shah, M.D., M.H.Sc. -
Leukapheresis for CAR-Therapy Manufacturing
Open - RecruitingNCI Protocol ID NCI-17-C-0137Investigator Nirali N. Shah, M.D., M.H.Sc. -
A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), in Children and Adults with Wild Type GIST, Pheochromocytoma and Paraganglioma Associated with Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Open - RecruitingNCI Protocol ID NCI-17-C-0088Investigator John W. Glod, M.D. -
A Phase I/II Trial of the Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination with the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients with Embryonal and Alveolar Rhabdomyosarcoma
Open - RecruitingNCI Protocol ID NCI-17-C-0049Investigator Christine M. Heske, M.D. -
A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination with UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults with Relapse of Acute Lymphoblastic Leukemia
Open - RecruitingNCI Protocol ID NCI-17-C-0028Investigator Nirali N. Shah, M.D., M.H.Sc.Share this trial: Referral ContactsContact Name Phone Number Nirali Shah, M.D., MHSc. (301) 451-0390 -
Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma
Open - RecruitingNCI Protocol ID NCI-16-C-0097Investigator John W. Glod, M.D. -
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Open - RecruitingNCI Protocol ID NCI-16-C-0043Investigator Brigitte C. Widemann, M.D. -
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
Open - RecruitingNCI Protocol ID NCI-15-C-0195Investigator Pamela L. Wolters, Ph.D. -
Acceptance and Commitment Training for Adolescents and Adults with Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial
Open - RecruitingNCI Protocol ID NCI-15-C-0142Investigator Staci Martin Peron, Ph.D. -
Phase I/II Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Open - RecruitingNCI Protocol ID NCI-15-C-0101Investigator Brigitte C. Widemann, M.D. -
Phase I/II Trial of PLX3397 in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Open - RecruitingNCI Protocol ID NCI-15-C-0093Investigator Rosandra N. Kaplan, M.D. -
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Open - RecruitingNCI Protocol ID NCI-15-C-0029Investigator Nirali N. Shah, M.D., M.H.Sc. -
Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials
Open - RecruitingNCI Protocol ID NCI-15-C-0028Investigator John W. Glod, M.D. -
Phase 1 Study of a Combination of the PARP inhibitor, Niraparib and/or Temozolomide in Patients with Previously Treated, Incurable Ewing's Sarcoma
Open - RecruitingNCI Protocol ID NCI-14-C-0129Investigator John W. Glod, M.D. -
A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors
Open - RecruitingNCI Protocol ID NCI-14-C-0116Investigator Pamela L. Wolters, Ph.D. -
An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults with Cancer and Other Life Threatening Illnesses
Open - RecruitingNCI Protocol ID NCI-14-C-0079Investigator Lori Wiener, Ph.D., DCSW, LCSW-C -
Understanding the Perceived Influence of Childhood Cancer on the Parents' Marital/partner Relationship: A Descriptive Study
Open - RecruitingNCI Protocol ID NCI-12-C-0206Investigator Lori Wiener, Ph.D., DCSW, LCSW-C -
Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma
Open - RecruitingNCI Protocol ID NCI-12-C-0178Investigator John W. Glod, M.D. -
A Phase 1 and Phase II and Retreatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Open - RecruitingNCI Protocol ID NCI-11-C-0191Investigator John W. Glod, M.D. -
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency
Open - RecruitingNCI Protocol ID NCI-10-C-0174Investigator Nirali N. Shah, M.D., M.H.Sc.Share this trial: Referral ContactsContact Name Phone Number NCI Pediatric Leukemia Lymphoma BMT Team (240)760-6970 -
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
Open - RecruitingNCI Protocol ID NCI-10-C-0086Investigator Rosandra N. Kaplan, M.D. -
Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1
Open - RecruitingNCI Protocol ID NCI-08-C-0079Investigator Brigitte C. Widemann, M.D.